What was the primary objective of the BRUIN CLL-314 trial?
To demonstrate superiority of pirtobrutinib over ibrutinib in progression-free survival
To demonstrate non-inferiority of overall response rate of pirtobrutinib compared to ibrutinib
To evaluate the safety profile of non-covalent BTK inhibitors in treatment-naive patients only